Tazemetostat
- Generic Name
- Tazemetostat
- Brand Names
- Tazverik
- Drug Type
- Small Molecule
- Chemical Formula
- C34H44N4O4
- CAS Number
- 1403254-99-8
- Unique Ingredient Identifier
- Q40W93WPE1
Overview
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Background
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Indication
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 prior systemic therapies. Additionally, it is indicated in adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Associated Conditions
- Locally Advanced Epithelioid Sarcoma
- Metastatic Epithelioid Sarcoma
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.